KaydedilenlerDerginizi ekleyin

Dergiler / Turkish Journal of Biology / 2019 / Cilt: 43 - Sayı: 3

Key actors in cancer therapy: epigenetic modifiers

Remzi Okan AKAR
Selin SELVİ
Engin ULUKAYA
Nazlıhan AZTOPAL
Sayfa
155–170
Yayın Tarihi
2019-06-13
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

The emerging role of epitranscriptome (RNA epigenetic) in cancer therapy has also been included in this review as a new avenue and potential target for the better management of cancer-beneficial epigenetic machinery.

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Epigenetic reprogramming plays a crucial role in the tumorigenicity and maintenance of tumor-specific gene expression that especially occurs through DNA methylation and/or histone modifications.
📊
Temel Bulgular & Veri:Here, we review the epigenetic modifiers that have already been used in the clinic and/or in clinical trials, related preclinical studies in cancer therapy, and the smart combination strategies that target cancer stem cells along with the other cancer cells.
💡
Sonuç & Katkı:The emerging role of epitranscriptome (RNA epigenetic) in cancer therapy has also been included in this review as a new avenue and potential target for the better management of cancer-beneficial epigenetic machinery.
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Epigenetic modifications · RNA epigenetic · anticancer drugs

Abstract

Epigenetic reprogramming plays a crucial role in the tumorigenicity and maintenance of tumor-specific gene expression that especially occurs through DNA methylation and/or histone modifications. It has well-defined mechanisms. It is known that alterations in the DNA methylation pattern and/or the loss of specific histone acetylation/methylation markers are related to several hallmarks of cancer, such as drug resistance, stemness, epithelial-mesenchymal transition, and metastasis. It has also recently been highlighted that epigenetic alterations are critical for the regulation of the stemlike properties of cancer cells (tumor-initiating cells; cancer stem cells). Cancer stem cells are thought to be responsible for the recurrence of cancer which makes the patient return to the clinic with metastatic tumor tissue. Hence, the dysregulation of epigenetic machinery represents potential new therapeutic targets. Therefore, compounds with epigenetic activities have become crucial for developing new therapy regimens (e.g., antimetastatic agents) in the fight against cancer. Here, we review the epigenetic modifiers that have already been used in the clinic and/or in clinical trials, related preclinical studies in cancer therapy, and the smart combination strategies that target cancer stem cells along with the other cancer cells. The emerging role of epitranscriptome (RNA epigenetic) in cancer therapy has also been included in this review as a new avenue and potential target for the better management of cancer-beneficial epigenetic machinery.

🔖

Bu Makaleye Atıf Yap

AKAR, R. O., SELVİ, S., ULUKAYA, E., AZTOPAL, N. (2019). Key actors in cancer therapy: epigenetic modifiers. Turkish Journal of Biology, Cilt: 43 - Sayı: 3, 155–170. https://ajindex.com/articles/181354

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (11)

  1. Annunziato A (2008). DNA packaging: nucleosomes and chromatin. Nature Education 1 (1): 26. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M et al. (2014). Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510 (7504): 278-282.
  2. Azad N S, El-Khoueiry A, Yin J, Oberg AL, Flynn P et al. (2017). Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand up 2 cancer study. Oncotarget 8 (21): 35326. Aztopal N, Erkisa M, Ari F, Dere E, Ulukaya E (2018a). Dual inhibition of Wnt/beta-catenin signaling and histone deacetylation as a new strategy to eliminate breast cancer stem cells by augmentation of apoptosis. In FEBS Open Bio (Vol. 8). Hoboken, NJ, USA: Wiley. pp. 301-301.
  3. Aztopal N, Erkisa M, Erturk E, Ulukaya E, Tokullugil AH, Ari F (2018b). Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells. Chemico-Biological Interactions 280: 51-58.
  4. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E et al. (2009). Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene 28 (2): 209-218.
  5. Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O et al. (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. Journal of Clinical Oncology 24 (2): 268-273.
  6. Bannister AJ, Kouzarides T (2011). Regulation of chromatin by histone modifications. Cell Research 21 (3): 381-395.
  7. Baylin SB (2005). DNA methylation and gene silencing in cancer. Nature Reviews Clinical Oncology 2 (S1), S4. Bernstein BE, Meissner A, Lander ES (2007). The mammalian epigenome. Cell 128 (4): 669-681.
  8. Bernstein BE, Mikkelsen TS, Xie X, Kamal M, Huebert DJ et al. (2006). A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 125 (2): 315-326.
  9. Bird A (2002). DNA methylation patterns and epigenetic memory. Genes & Development 16 (1): 6-21.
  10. Blumenschein GR, Kies MS, Papadimitrakopoulou VA, Lu C, Kumar AJ et al. (2008). Phase II trial of the histone deacetylase inhibitor vorinostat (Zolinza™, suberoylanilide hydroxamic acid, SAHA) in patients with recurrent and/or metastatic head and neck cancer. Investigational New Drugs 26 (1): 81-87.
  11. Bracken AP, Dietrich N, Pasini D, Hansen KH, Helin K (2006). Genome-wide mapping of Polycomb target genes unravels th